文献速递乳腺癌

他莫昔芬治疗绝经后Luminal A/B型乳腺癌的远期无远处复发生存评估

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
PubMed 文献 · JAMA Oncol · 2019-01-01

该研究为STO-3试验的二次分析,比较绝经后淋巴结阴性Luminal A或B型乳腺癌患者接受他莫昔芬辅助治疗与否的远期无远处复发间期(DRFI)。结果显示他莫昔芬可降低两亚型复发风险,但Luminal A获益持续约15年,Luminal B获益仅约5年,且Luminal B早期复发风险更高。

要点

  • Luminal A型他莫昔芬获益持续15年(HR 0.57, 95%CI 0.35-0.94)。
  • Luminal B型他莫昔芬获益仅约5年(HR 0.38, 95%CI 0.24-0.59)。
  • 25年DRFI:治疗组Luminal A 87% vs B 67%;未治疗组70% vs 54%。

核心结论

  • Luminal A型肿瘤存在远期远处转移风险,他莫昔芬治疗可降低该风险。
  • Luminal B型肿瘤远处转移风险出现较早,他莫昔芬获益随时间衰减。

研究设计与样本

  • STO-3试验的二次分析,该试验于1976-1990年将绝经后淋巴结阴性乳腺癌患者随机分配至他莫昔芬辅助治疗或无内分泌治疗。
  • 2014年用免疫组化和Agilent微阵列评估肿瘤组织,仅纳入Luminal A或B型患者。
  • 治疗组Luminal A 183例、Luminal B 64例;未治疗组Luminal A 153例、Luminal B 62例;诊断年龄45-73岁。

主要发现

  • 按治疗组别DRFI差异有统计学意义:Luminal A亚型n=336,log rank P < .001;Luminal B亚型n=126,P = .04。
  • 25年DRFI:治疗组Luminal A为87%(95%CI 82%-93%),Luminal B为67%(95%CI 56%-82%)。
  • 25年DRFI:未治疗组Luminal A为70%(95%CI 62%-79%),Luminal B为54%(95%CI 42%-70%)。
  • Luminal A型患者诊断后15年内显著从他莫昔芬治疗中获益(HR 0.57;95%CI 0.35-0.94)。
  • Luminal B型患者从他莫昔芬治疗中获益持续5年(HR 0.38;95%CI 0.24-0.59)。

关键数值与推荐

  • 他莫昔芬治疗至少2年;无复发且再次知情同意的患者进一步随机接受额外3年他莫昔芬治疗或无内分泌治疗。
  • 采用Kaplan-Meier分析和时间依赖灵活参数模型估计校正患者和肿瘤特征的时间变化风险比(HR)。

临床怎么用

  • 对绝经后淋巴结阴性Luminal A型乳腺癌患者,他莫昔芬辅助治疗可带来长期远处复发获益,支持长期随访和内分泌治疗决策。
  • 对Luminal B型患者,他莫昔芬获益主要集中在诊断后早期,需关注早期复发风险及后续治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with estrogen receptor (ER)-positive breast cancer have a long-term risk for fatal disease. However, the tumor biological factors that influence the long-term risk and the benefit associated with endocrine therapy are not well understood. OBJECTIVE: To compare the long-term survival from tamoxifen therapy for patients with luminal A or luminal B tumor subtype. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of patients from the Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal patients with lymph node-negative breast cancer to receive adjuvant tamoxifen or no endocrine therapy. Tumor tissue sections were assessed in 2014 using immunohistochemistry and Agilent microarrays. Only patients with luminal A or B subtype tumors were evaluated. Complete long-term follow-up data up to the end of the STO-3 trial on December 31, 2012, were obtained from the Swedish National registers. Data analysis for the secondary analysis was conducted in 2017 and 2018. INTERVENTIONS: Patients were randomized to receive at least 2 years of tamoxifen therapy or no endocrine therapy; patients without recurrence who reconsented were further randomized to 3 additional years of tamoxifen therapy or no endocrine therapy. MAIN OUTCOMES AND MEASURES: Distant recurrence-free interval (DRFI) by luminal A and luminal B subtype and trial arm was assessed by Kaplan-Meier analyses and time-dependent flexible parametric models to estimate time-varying hazard ratios (HRs) that were adjusted for patient and tumor characteristics. RESULTS: In the STO-3 treated trial arm, 183 patients had luminal A tumors and 64 patients had luminal B tumors. In the untreated arm, 153 patients had luminal A tumors and 62 had luminal B tumors. Age at diagnosis ranged from 45 to 73 years. A statistically significant difference in DRFI by trial arm was observed (log rank, P < .001 [luminal A subtype, n = 336], P = .04 [luminal B subtype, n = 126]): the 25-year DRFI for luminal A vs luminal B subtypes was 87% (95% CI, 82%-93%) vs 67% (95% CI, 56%-82%) for treated patients, and 70% (95% CI, 62%-79%) vs 54% (95% CI, 42%-70%) for untreated patients, respectively. Patients with luminal A tumors significantly benefited from tamoxifen therapy for 15 years after diagnosis (HR, 0.57; 95% CI, 0.35-0.94), and those with luminal B tumors benefited from tamoxifen therapy for 5 years (HR, 0.38; 95% CI, 0.24-0.59). CONCLUSIONS AND RELEVANCE: Patients with luminal A subtype tumors had a long-term risk of distant metastatic disease, which was reduced by tamoxifen treatment, whereas patients with luminal B tumors had an early risk of distant metastatic disease, and tamoxifen benefit attenuated over time.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yu NY, Iftimi A, Yau C, et al. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. JAMA Oncol. 2019. PMID: 31393518. doi:10.1001/jamaoncol.2019.1856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。